"A co-packaged combination of four drugs for second-line antiretroviral treatment for developing countries will be made available from early 2010 for $425, the Clinton HIV/AIDS Initiative announced today.
"With immediate effect the drugs —tenofovir, lamivudine (3TC), atazanavir and a boosting dose of ritonavir—will be available at a price of $475. That’s $115 less than the previous cheapest option for second-line treatment, lopinavir/ritonavir plus tenofovir/3TC, currently being offered to qualifying countries in the developing world by the Clinton HIV/AIDS Initiative Procurement Consortium at a ceiling price of $590 a year. "
Read more in Aidsmap, August 6, 2009.
1 comments:
There was an error this report, that indicated that the new combination will include emtricitabine (as quoted in this post). That should read 3TC (lamivudine). This error has been corrected in the AIDSmap report.
Chris
Post a Comment